SEPN Septerna, Inc.

NASDAQ
$40.02

Septerna, Inc. (SEPN) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.9% since its last earnings release on November 9, 2026.

Septerna Missed Consensus Estimates
Monday, November 9, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.57)
Rev est $20.33M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $44.34

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Septerna, Inc.

Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.